Literature DB >> 26698214

A rare and life-threatening cause of epistaxis.

Rory McDonald1, Anant Piyush Patel1, Claudine Horrocks1.   

Abstract

Epistaxis is a potentially life-threatening condition that can compromise a patient's airway, breathing and circulation. Early recognition of underlying bleeding diatheses that are amenable to medical therapy is imperative in order for timely treatment and to reduce morbidity. We present a case in which acquired haemophilia was diagnosed in an 83-year-old man presenting with seemingly uncomplicated epistaxis. The patient suffered multisite haemorrhages and haemodynamic compromise before definitive management with monoclonal antibody therapy. The case highlights the difficulties in managing this rare condition. It also emphasises the importance of clotting assay analysis in patients who present with epistaxis in the absence of an underlying anticoagulant. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26698214      PMCID: PMC4691919          DOI: 10.1136/bcr-2015-213528

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

Authors:  Peter W Collins; Sybil Hirsch; Trevor P Baglin; Gerard Dolan; John Hanley; Michael Makris; David M Keeling; Ri Liesner; Simon A Brown; Charles R M Hay
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

2.  Management of epistaxis: a national survey.

Authors:  B Kotecha; S Fowler; P Harkness; J Walmsley; P Brown; J Topham
Journal:  Ann R Coll Surg Engl       Date:  1996-09       Impact factor: 1.891

3.  The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.

Authors:  C R Hay; C Negrier; C A Ludlam
Journal:  Thromb Haemost       Date:  1997-12       Impact factor: 5.249

4.  Case report: successful use of antifibrinolytic therapy in acquired factor VIII deficiency.

Authors:  R B Lalwani; R B Stricker
Journal:  Am J Med Sci       Date:  1992-06       Impact factor: 2.378

5.  A population based, unselected, consecutive cohort of patients with acquired haemophilia A.

Authors:  Peter Collins; Nicola Macartney; Richard Davies; Steven Lees; John Giddings; Ray Majer
Journal:  Br J Haematol       Date:  2004-01       Impact factor: 6.998

6.  A survey of 215 non-hemophilic patients with inhibitors to Factor VIII.

Authors:  D Green; K Lechner
Journal:  Thromb Haemost       Date:  1981-06-30       Impact factor: 5.249

Review 7.  Advances in the understanding of acquired haemophilia A: implications for clinical practice.

Authors:  Peter W Collins; Charles L Percy
Journal:  Br J Haematol       Date:  2009-10-07       Impact factor: 6.998

8.  Treatment of acquired haemophilia with factor eight inhibitor bypassing activity.

Authors:  S Sallah
Journal:  Haemophilia       Date:  2004-03       Impact factor: 4.287

9.  Acute onset dysphagia associated with an intramural oesophageal haematoma in acquired haemophilia.

Authors:  Paul Horan; Mary Drake; R Neil Patterson; Robert J G Cuthbert; Declan Carey; Simon D Johnston
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-02       Impact factor: 2.566

10.  Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment.

Authors:  I Hauser; B Schneider; K Lechner
Journal:  Thromb Haemost       Date:  1995-01       Impact factor: 5.249

View more
  1 in total

1.  Recurrent epistaxis secondary to nasal haemangioma with a misleading CT angiogram.

Authors:  Oliver Wright; Philippe Bowles; Andrew Pelser
Journal:  BMJ Case Rep       Date:  2019-06-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.